{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001515","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.352116+00:00","generated_at":"2026-06-04T10:02:30.875185+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Compass Therapeutics reports FY2023 net loss of $42.5M; CTX-009 data expected by end 2024","bullets":["Net loss $42.5M ($0.33/share) vs $39.2M loss in 2022; R&D expenses rose 27% to $38.1M.","Cash and marketable securities $152.5M at Dec 31, 2023; runway into mid-2026.","CTX-009 Phase 2/3 BTC study (COMPANION-002) enrollment ongoing; top-line data expected year-end 2024.","CTX-009 Phase 2 CRC study (COMPANION-003) Stage 1 enrollment complete; top-line data mid-2024.","CTX-471 Phase 2 monotherapy planning underway for melanoma with novel biomarker; combination arm with KEYTRUDA enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001515","json":"https://secwatch.observer/filing/0001171843-24-001515.json","markdown":"https://secwatch.observer/filing/0001171843-24-001515.md","text":"https://secwatch.observer/filing/0001171843-24-001515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/0001171843-24-001515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/f8k_032024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:02:30.875185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9af79d2af29b43c801d491056d038d778027776","claim":"Compass Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $42.5 million or $0.33 per common share, EPS $0.33 per common share.","evidence_excerpt":"On March 21, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324001515/0001171843-24-001515-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023, was $42.5 million or $0.33 per common share"},{"label":"EPS","value":"$0.33 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}